Corporate | 7 March 2007 10:00
Planegg-Martinsried, Germany, 07 March 2007
– 4SC AG (Frankfurt, Prime Standard: VSC), a German drug discovery and development company announced today that the company will be presenting at BioSquare 2007. The conference is being held at the Convention Center in Lyon, France on March 12 to 15, 2007.
The presentation will be given by Dr Ulrich Dauer, Chief Executive Officer of 4SC AG on Tuesday, 13 March 2007 at 5.15 p.m. local time in room ‘Rhone 2’. Dr Dauer will give a review of the company and update the audience on current developments at 4SC AG, including the progress within 4SC’s clinical project as well as further news from its project pipeline.
About 4SC
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 59, the company develops novel drug candidates for inflammatory diseases and cancer using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC AG uses its patented technology platform to create a sustainable product pipeline for active agents that are developed in early clinical phases (‘proof of concept’) and subsequently result in upfront and milestone payments as well as participation in sales generated by out-licensed products to the pharmaceutical industry. There are currently five projects in the pipeline. The first project on the treatment of rheumatoid arthritis is currently undergoing clinical phase IIa. Three other product candidates are in pre-clinical development and another project is in the research stage. Furthermore, the company has its technology platform in co-operation projects with biotech and pharma companies and is already generating initial revenues.
Legal Note
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.